Nabriva scores its first FDA nod with novel antibiotic Xenleta

19th August 2019 Uncategorised 0

With drug-resistant bacteria on the rise, antibiotics have struggled to keep up with the challenge. Now, with the FDA’s approval of a new antibiotic for bacterial pneumonia, some of that may change. Monday, the FDA approved Nabriva Therapeutics’ Xenleta (lefamulin) to treat community-acquired bacterial-pneumonia (CABP).

More: Nabriva scores its first FDA nod with novel antibiotic Xenleta
Source: fierce